Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential

  title={Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential},
  author={C. Heather Ashton and P. Brian Moore and Peter Gallagher and Allan H. Young},
  journal={Journal of Psychopharmacology},
  pages={293 - 300}
Bipolar affective disorder is often poorly controlled by prescribed drugs. Cannabis use is common in patients with this disorder and anecdotal reports suggest that some patients take it to alleviate symptoms of both mania and depression. We undertook a literature review of cannabis use by patients with bipolar disorder and of the neuropharmacological properties of cannabinoids suggesting possible therapeutic effects in this condition. No systematic studies of cannabinoids in bipolar disorder… 

Figures and Tables from this paper

Prospects for the Use of Cannabinoids in Psychiatric Disorders
The prospects of using the psychoactive effects of cannabinoids in treating mental and psychiatric disorders are discussed, however, this evidence is weak for some clinical conditions and well-designed randomized controlled trials are currently lacking.
Bipolar Disorder and Comorbid Use of Illicit Substances
Substance use disorders (SUD) are highly prevalent in bipolar disorder (BD) and significantly affect clinical outcomes. Incidence and management of illicit drug use differ from alcohol use disorders,
Cannabis and psychiatric disorders: it is not only addiction
It became apparent that cannabis use is not only frequent in patients suffering from BD, but that it also induces manic symptoms in this group and cannabinoid compounds could display a new class of medication, as suggested by the fatty acid amino hydrolase inhibitor URB597 in animal models.
Cannabidiol as a potential treatment for psychosis
CBD, a non-intoxicating constituent of the cannabis plant, has emerged as a potential novel class of antipsychotic with a unique mechanism of action and the prospects of CBD as a possible novel treatment for psychotic disorders are set out.
Cannabidiol was ineffective for manic episode of bipolar affective disorder
The preliminary data suggest that CBD may not be effective for the manic episode of BAD, and the efficacy, tolerability and side effects were assessed.
[Therapeutical use of the cannabinoids in psychiatry].
Cannabidiol was found to have therapeutic potential with antipsychotic, anxiolytic, and antidepressant properties, in addition to being effective in other conditions, and Delta(9)-tetrahydrocannabinol and its analogues were shown to have anxIOlytic effects in the treatment of cannabis dependence.
Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.
The present article reviews the currently available knowledge on the herbal, synthetic and endogenous cannabinoids with respect to the modulation of anxiety responses, and highlights the challenges that should be overcome to harness the therapeutic potential of some of these compounds, all the while limiting the side effects associated with cannabis consumption.
The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders
The literature on the effects of cannabinoids is reviewed and the possibility of enhancing cannabinoid activity on psychiatric symptoms by the addition of terpenes and terpenoids is discussed, suggesting the “entourage effect” is the suggested positive contribution derived from the added of ter penes to cannabinoids.
Cannabinoids and Neuropsychiatric Disorders
This chapter provides an overview of some of the biological effects of a number of the cannabinoids and terpenes, as well as discussing their known mechanisms of action and evidence of potential therapeutic effects.


The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research.
The authors present case histories indicating that a number of patients find cannabis (marihuana) useful in the treatment of their bipolar disorder, and describe the use of cannabis as a supplement to lithium or for relief of lithium's side effects.
Drug abuse and bipolar disorder: comorbidity or misdiagnosis?
The Pharmacological Treatment of Bipolar Affective Disorder: Practice Is Improving but Could Still be Better
Practice in the population studied is nearer than treatment described in previous work to that suggested in the literature, but it still falls short in a number of respects of such recommendations as exist and this requires further examination and monitoring.
Does Quetiapine Have Mood Altering Properties?
These cases indicate that a side-effect of quetiapine may be mood elevation, an ability to elevate mood while controlling psychoses would be helpful in the treatment of post-psychotic and bipolar depression.
Psychiatric effects of cannabis
  • A. Johns
  • Medicine, Psychology
    British Journal of Psychiatry
  • 2001
To re-evaluate the adverse effects of cannabis in the general population and among vulnerable individuals, including those with serious psychiatric disorders, a wide-ranging review of the topics related to these issues is conducted.
Anticonvulsants as mood stabilisers
Research into the use of anticonvulsants as alternatives or supplements to lithium in the treatment of bipolar affective disorder, particularly when outcome is poor, is highlighted.
Hypnotic and Antiepileptic Effects of Cannabidiol
Abstract: Clinical trials with cannabidiol (CBD) in healthy volunteers, insomniacs, and epileptic patients conducted in the authors' laboratory from 1972 up to the present are reviewed. Acute doses
The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis
It is indicated that Δ-9-THC produces a broad range of transient symptoms, behaviors, and cognitive deficits in healthy individuals that resemble some aspects of endogenous psychoses and warrant further study of whether brain cannabinoid receptor function contributes to the pathophysiology of psychotic disorders.